EJNMMI Research

Table 2 The RPPA markers that showed significant modulations after 3 days of the RO4987655 treatment

From: Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [¹⁸F] FDG-PET imaging combined with proteomic approaches

Analyte	Pvalue	Pathway
	Down-regulated
ERK1/2-P-Thr202/Tyr204-rbm	0.00001	MAPK
EGFR-P-Tyr1068	0.0058	RTK
MKK4-P-Ser257/Thr261	0.0483	MAPK
	Up-regulated
MEK1/2-P-Ser217/221	0.00098	MAPK
Akt-P-Ser473	0.0034	Akt/metabolism
c-Met	0.0242	RTK
P53-P-Ser392	0.025	Cell cycle control
Cyclin D1	0.0302	Cell cycle control
C-Raf-P-Ser338	0.0371	MAPK
MEK2	0.0433	MAPK

Back to article page